Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies.
BACKGROUND
Adalimumab, a fully human monoclonal antibody, binds to and neutralizes tumor necrosis factor.


OBJECTIVE
To provide an integrated review of efficacy and safety from adalimumab clinical trials in psoriasis.


METHODS
Pooled analyses were conducted of three placebo-controlled clinical trials of adalimumab (40 mg every other week) in psoriasis patients. The primary efficacy measure was the Psoriasis Area Severity Index (PASI). The Physician's Global Assessment (PGA) was also assessed.


RESULTS
At Week 16, mean percentage PASI improvement was 78.3% for adalimumab-treated patients versus 15.1% for placebo-treated patients. A PGA of "Clear" or "Minimal" was achieved in 63.4% of adalimumab-treated patients versus 5.1% of placebo-treated patients. The response to adalimumab was rapid, with significant improvements for adalimumab-treated patients in most efficacy measures by Week 4. Adverse event incidence was similar between treatment groups and consistent with adalimumab safety profiles in other indications.


CONCLUSIONS
Adalimumab improved psoriasis and was generally safe and well-tolerated.
Probity Medical Research, University of Western Ontario, Waterloo, ON. kapapp@probitymedical.com
Kim
K
Papp
Martin
M
Okun
Ronald
R
Vender
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab